EphA3 biology and cancer.

Abstract

Eph receptor tyrosine kinases control cell-cell interactions during normal and oncogenic development, and are implicated in a range of processes including angiogenesis, stem cell maintenance and metastasis. They are thus of great interest as targets for cancer therapy. EphA3, originally isolated from leukemic and melanoma cells, is presently one of the most promising therapeutic targets, with multiple tumor-promoting roles in a variety of cancer types. This review focuses on EphA3, its functions in controlling cellular behavior, both in normal and pathological development, and most particularly in cancer.

• Authors: Peter W Janes, Christopher I Slape, Rae H Farnsworth, Lakmali Atapattu, Andrew M Scott, Mary E Vail
• Journal: Growth factors (Chur, Switzerland) (Growth Factors) Vol. 32 Issue 6 Pg. 176-89 (Dec 2014) ISSN: 1029-2292 [Electronic] England
• PMID: 25391995 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Protein Kinase Inhibitors
• Receptors, Eph Family

Topics

• Animals
• Antineoplastic Agents (pharmacology, therapeutic use)
• Humans
• Neoplasms (drug therapy, metabolism)
• Protein Kinase Inhibitors (pharmacology, therapeutic use)
• Receptors, Eph Family (antagonists & inhibitors, chemistry, genetics, metabolism)